|
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy Clinical research trials and BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy. BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy clinical trial. Subjects often receive the most expert healthcare possible for their BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy  BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
For Condition: stage 4 esophageal cancer,Adenocarcinoma of the Esophagus,recurrent gastric cancer,adenocarcinoma of the stomach,stage 4 gastric cancer,recurrent esophageal cancer
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent metastatic stomach cancer that has been previously treated with chemotherapy.
Details: OBJECTIVES: I. Determine the clinical activity of BMS-247550 in terms of response rate in patients with recurrent metastatic gastric cancer previously treated with a fluoropyrimidine or platinum regimen. II. Determine the safety of this drug in this patient population. III. Determine the duration of response, time to progression, and survival of patients treated with this drug. PROTOCOL OUTLINE: This is a multicenter study. Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive up to 4 additional courses after CR. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 21-58 patients will be accrued for this study within 12 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed recurrent metastatic adenocarcinoma of the stomach or gastroesophageal junction; No squamous cell or sarcomatous elements in tumor - Previously treated with 1 prior fluoropyrimidine and/or platinum based chemotherapy regimen for metastatic disease OR Recurrent disease within 6 months of completing adjuvant fluoropyrimidine-containing therapy - Bidimensionally measurable disease - No known brain metastases --Prior/Concurrent Therapy-- - Biologic therapy: No concurrent immunotherapy - Chemotherapy: See Disease Characteristics; At least 3 weeks since prior chemotherapy; Prior adjuvant or neoadjuvant chemotherapy allowed; No more than 1 prior chemotherapy regimen for metastatic disease; No prior taxane therapy; No other concurrent chemotherapy - Endocrine therapy: No concurrent hormonal therapy except hormone replacement therapy - Radiotherapy: At least 3 weeks since prior radiotherapy and recovered; No prior radiotherapy to major bone marrow-containing areas (pelvis, lumbar spine) or to only site of measurable disease; No concurrent therapeutic radiotherapy - Surgery: At least 1 week since prior minor surgery and recovered; At least 3 weeks since prior major surgery and recovered - Other: No other concurrent experimental anticancer medications --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2 - Life expectancy: At least 12 weeks - Hematopoietic: Absolute neutrophil count at least 2,000/mm3; Platelet count greater than 125,000/mm3 - Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN); ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present) - Renal: Creatinine no greater than 2 times ULN - Cardiovascular: No unstable angina, myocardial infarction, or congestive heart failure within the past 6 months - Other: No grade 2 or greater neuropathy (motor or sensory); No other malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the cervix; No serious concurrent infection; No other medical illness that would preclude study; No psychiatric disorder or other condition that would preclude study; No known hypersensitivity to Cremophor EL; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception during and for 2 months after study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ManishShah, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000068645; MSKCC-01015,NCI-G01-1950
Study Start Date: February 2001
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00017056
Other Adenocarcinoma Of The Esophagus Studies:
1. Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
2. T900607 in Treating Patients With Gastroesophageal Junction Cancer
3. Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
4. Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
5. DX-8951f in Treating Patients With Metastatic Stomach Cancer
Related Studies:
Other Adenocarcinoma of the Esophagus Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
|
|
|
|
|
|
|
|
